[go: up one dir, main page]

MX2017003015A - Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos. - Google Patents

Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.

Info

Publication number
MX2017003015A
MX2017003015A MX2017003015A MX2017003015A MX2017003015A MX 2017003015 A MX2017003015 A MX 2017003015A MX 2017003015 A MX2017003015 A MX 2017003015A MX 2017003015 A MX2017003015 A MX 2017003015A MX 2017003015 A MX2017003015 A MX 2017003015A
Authority
MX
Mexico
Prior art keywords
metastases
solid cancers
treating solid
predicting
medicaments
Prior art date
Application number
MX2017003015A
Other languages
English (en)
Inventor
Staub Eike
Straub Josef
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017003015A publication Critical patent/MX2017003015A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un nuevo método para tratar cáncer colorectal (CRC) y metástasis del mismo en sujetos, y de manera preferente también de otros cánceres sólidos y metástasis de los mismos en sujetos, en donde el método depende de manera preferente en si el paciente muestra ciertos niveles de proteínas específicos en uno o más fluidos corporales antes de o durante el tratamiento, en donde el tratamiento comprende la administración de al menos uno inhibidor de integrina pan a? a un paciente, un medicamento para el uso en los nuevos métodos y un método para predecir el resultado de un tratamiento con al menos un inhibidor de integrina pan a? basado en los niveles de proteínas específicos en uno o más fluidos corporales del paciente.
MX2017003015A 2014-09-17 2015-08-18 Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos. MX2017003015A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051530P 2014-09-17 2014-09-17
PCT/EP2015/001699 WO2016041614A1 (en) 2014-09-17 2015-08-18 A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof

Publications (1)

Publication Number Publication Date
MX2017003015A true MX2017003015A (es) 2017-05-23

Family

ID=53969334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003015A MX2017003015A (es) 2014-09-17 2015-08-18 Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.

Country Status (14)

Country Link
US (2) US11415581B2 (es)
EP (1) EP3193927B1 (es)
JP (2) JP7372025B2 (es)
KR (1) KR20170052690A (es)
CN (1) CN107073111A (es)
AU (2) AU2015317409A1 (es)
BR (1) BR112017005336A2 (es)
CA (1) CA2961421C (es)
ES (1) ES2856348T3 (es)
IL (1) IL251078B (es)
MX (1) MX2017003015A (es)
RU (1) RU2017112998A (es)
SG (1) SG11201702135PA (es)
WO (1) WO2016041614A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015317411A1 (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
CA3116669A1 (en) * 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
EP4527386A1 (en) * 2023-09-20 2025-03-26 Eberhard-Karls-Universität Tübingen Universitätsklinikum Anti-cancer pharmaceutical composition comprising regorafenib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
DE69531187T2 (de) 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
CN1277545C (zh) 2001-05-02 2006-10-04 诺瓦提斯公司 二膦酸类化合物在制备用于治疗与前列腺癌有关的骨转移瘤的药物中的用途
US20050159361A1 (en) 2002-03-11 2005-07-21 Takahito Hara Remedies for sex hormone-dependent disease
JP2004002321A (ja) 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
WO2004090550A2 (en) 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
CA2638750A1 (en) * 2006-03-02 2007-09-13 Laboratory Corporation Of America Holdings Methods and systems for evaluating health risk factors by measurement of dna damage and dna repair
EA019485B1 (ru) 2007-07-17 2014-04-30 Мерк Патент Гмбх Сконструированные гибридные антитела против альфа v интегрина
JP5403534B2 (ja) 2008-10-29 2014-01-29 インフォコム株式会社 食道癌の予後予測のための情報を提供する方法
AU2009331955B2 (en) 2008-12-23 2015-09-24 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
SG10201604988YA (en) * 2008-12-23 2016-07-28 Genentech Inc Methods and compositions for diagnostic use in cancer patients
US20120039805A1 (en) 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
EA201200025A1 (ru) 2009-06-19 2012-07-30 Мерк Патент Гмбх Биомаркеры и способы определения эффективности анти-egfr антител для лечения злокачественного новообразования
KR101557545B1 (ko) 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
WO2012024612A1 (en) * 2010-08-20 2012-02-23 Pangea Biosciences, Inc. Cancer diagnostic and cancer therapeutic
MX352025B (es) 2011-02-11 2017-11-07 Merck Patent Gmbh Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
ES2550192T3 (es) 2011-05-25 2015-11-05 Novartis Ag Biomarcadores para el cáncer de pulmón
WO2012167028A2 (en) 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
HK1200739A1 (en) 2012-03-30 2015-08-14 霍夫曼-拉罗奇有限公司 Diagnostic methods and compositions for treatment of cancer
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
AU2015317411A1 (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

Also Published As

Publication number Publication date
CA2961421A1 (en) 2016-03-24
JP2021009154A (ja) 2021-01-28
KR20170052690A (ko) 2017-05-12
RU2017112998A (ru) 2018-10-17
ES2856348T3 (es) 2021-09-27
IL251078A0 (en) 2017-04-30
US20170298134A1 (en) 2017-10-19
JP7242617B2 (ja) 2023-03-20
IL251078B (en) 2021-05-31
JP7372025B2 (ja) 2023-10-31
EP3193927A1 (en) 2017-07-26
US20220334117A1 (en) 2022-10-20
US11415581B2 (en) 2022-08-16
WO2016041614A1 (en) 2016-03-24
AU2015317409A1 (en) 2017-04-27
JP2017535516A (ja) 2017-11-30
BR112017005336A2 (pt) 2017-12-12
RU2017112998A3 (es) 2019-03-28
CA2961421C (en) 2024-01-30
EP3193927B1 (en) 2020-11-25
CN107073111A (zh) 2017-08-18
AU2021203352A1 (en) 2021-06-24
SG11201702135PA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2022008868A (es) Tratamiento del cancer con tg02.
CY1122143T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα
MX2017003406A (es) Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
EP3544483A4 (en) SYSTEM AND METHOD OF DISEASE DIAGNOSIS, TREATMENT AND PROGNOSIS DETERMINATION
MX2019011148A (es) Metodos de tratamiento.
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
MX387627B (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
MY176219A (en) Combination therapy for cancer
MX2017003015A (es) Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.
HK1253320A1 (zh) 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
MX2024008740A (es) Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
WO2019053116A8 (en) Method for guidance of fluid therapy based on proadrenomedullin
WO2015144184A8 (en) Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer
UA93328U (uk) Спосіб прогнозування незрощеного перелому
UA104420U (uk) Спосіб прогнозування зрощення перелому
UA107731U (uk) Спосіб прогнозування зрощення перелому